|
|
Blood, Vol. 111, Issue 3, 1124-1127, February 1, 2008
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia
Blood Archambeault et al.
111: 1124
Supplemental materials for: Archambeault et al
Files in this Data Supplement:
- Table S1. Digestions, primers and probes for each TaqMAMA assay (PDF, 54.7 KB)
- Table S2. Reaction buffer recipes (PDF, 56.7 KB)
- Table S3. Median levels of mutant DNA pre-HSCT with subsequent achievement of clinical remission after HSCT (PDF, 21.2 KB)
- Figure S1. Wild type false positive rates by assay (JPG, 56.4 KB)
-
WT controls were run on each TaqMAMA plate and used to calculate a mean false positive rate for each assay.
- Figure S2. Concordance of bone marrow and peripheral blood samples (JPG, 52.5 KB)
-
Percent mutant DNA by TaqMAMA is graphed for 7 pairs of BM and PB taken on the same or consecutive day. Six pairs were negative (1-6) for a mutation in both BM and PB, and an additional three samples had > 5% mutant DNA in both samples (14-16) (data not shown).
- Figure S3. Earliest detected chimerism by TaqMAMA and autologous cells in relapsing patients post-HSCT (JPG, 105 KB)
-
TaqMAMA detected chimerism earlier than autologous cells in five of eight relapsing patients following HSCT. Both methods detected chimerism at the same time in the remaining three patients. Shown below are the TaqMAMA mutant DNA and autologous cell levels detected in samples from the first day TaqMAMA detected chimerism until the first day microsatellite analysis detected chimerism. The patients shown are A) D098, KRAS 38G>A; B) D292, PTPN11 227A>G; C) D361, NRAS 38G>A; D) D405, NRAS 37G>C; E) I160, PTPN11 226G>A.
|
|
